Healthcare Webinars

Medication errors are a leading cause of injury and avoidable harm in healthcare, with an estimated 1.3 million people impacted in the U.S. each year. Preventable medication errors cost the nation more than $21 billion annually across all care settings, representing a serious public health concern, as well as an economic burden on our healthcare system. Join AHRQ’s expert panel of speakers to hear how quality improvement approaches and digital healthcare interventions such as clinical decision support tools are reducing medication errors, improving provider effectiveness, and enhancing patient safety in a variety of clinical care settings. CE/CME accreditation of this activity is pending; if approved, eligible providers can earn up to 1.5 CE/CME contact hours for participating in the live webinar.Learning Objectives:At the conclusion of this Webinar, participants should be able to:• Discuss how an e-prescribing tool can reduce medication discrepancies and improve patient safety by enhancing communication between pharmacists and providers.• Identify how clinical decision support systems can significantly reduce the prescribing of potentially inappropriate medications to older patients at the time of discharge from the emergency department setting.• Explain how outcome measures, such as the Wrong-Patient Retract-and-Reorder measure, can be developed and used to detect medication errors in electronic orders.Speakers: Samantha Pitts, M.D., M.P.H. (Assistant Professor, Department of Medicine, Johns Hopkins University School of Medicine), Camille P. Vaughan, M.D., M.S. (Director, Associate Professor of Medicine, Division of Geriatrics & Gerontology, Emory School of Medicine), Jason Adelman, M.D., M.S. (Director, Associate Dean for Quality and Patient Safety, Center for Patient Safety Science, Columbia University).Moderator: James Swiger, M.B.E. (Health Scientist Administrator, Division of Digital Healthcare Research, Center for Evidence and Practice Improvement, AHRQ).

In the ever-evolving healthcare landscape, optimizing patient experiences remains a paramount goal. This presentation will share Penn Medicine’s story about the intricacies of omnichannel contact center transformation focused on technology, agent and patient experience, and the ultimate goal of creating a world class customer experience for their patients. We will explore how to show consistent progress towards core business problems and why operational changes are needed along with technology. Finally, we will highlight how establishing a strong data and governance foundation can help pave the way for the future of AI tools and technologies. Learning Topics:• How to define the business problems that will improve patient experiences• How to stay the course during a multi-year transformation• How to establish sound operating cross-organization structures and practices• How to set up a rich data foundation to build towards automation and AI features in the futurePresenters:Robin Ward - Associate Vice President, Enterprise Customer Analytics and Marketing Technology, Penn MedicineCalvin Jordan - Associate Vice President, Patient Access, Penn MedicineAaron Johnson - Associate Vice President, Patient and Consumer Engagement, Penn MedicineHosts:Ellie Rice - Slalom Healthcare and Life Sciences LeaderZach Lewis - Salesforce Industry Partner Advisor - Healthcare and Life Sciences

We are excited to invite you to our upcoming webinar, "Glaucoma Medications: From Drops to Implants," featuring Arpine Barsegian, MD. This informative session will delve into the latest advancements in glaucoma treatments, covering a comprehensive range of medication options from traditional eye drops to innovative implant technologies.Speakers: Michelle de Elizalde (Assistant Director of Patient and Research Programs) and Arpine Barsegian, MD (Ophthalmologist)

Monoclonal antibodies represent a highly successful class of therapeutics that are used to treat complex diseases across a wide range of therapeutic areas. However, their high cost and variable patient response underscores the need for new modalities that can be used to activate or suppress the immune system. Aptamers have long been viewed as a simpler alternative to antibodies, but challenges with biostability, effectiveness, and throughput have slowed their progress in the clinic. In this talk, I will discuss a path for democratizing antibody therapeutics that relies a class of molecules called threomers, which are highly functionalized synthetic nucleic acids assembled on a biologically stable threose nucleic acid (TNA) framework. I will describe the underlying chemistry and enzyme engineering developed to support a high throughput discovery pipeline and provide examples of recently discovered threomers that mirror the binding properties of antibodies.Speaker: John Chaput, PhD, Professor - University of California, Irvine

Learner Outcomes: By the end of this webinar, attendees should be able to articulate why it’s important to consider a patient community audience when planning scientific and data dissemination including incorporating their voice within it. They will also gain confidence to follow clear methodologies to incorporate the patient voice within publications and understand the role of Medical Affairs in disease awareness campaigns. Additionally, participants will learn best practice approaches including novel ways to disseminate information.Speakers: Tracy Hart (CEO, Osteogenesis Imperfecta foundation) and Gavin Jones (Global Healthcare Agency Lead, Lumanity).

Losing a partner is a life-changing experience. We draw on numerous datasets to examine differences between widowed and partnered older women and to provide a comprehensive picture of well-being in widowhood. Most importantly, our analysis accounts for time use in widowhood, an aspect which has not been studied previously. Based on data from several European countries we trace the evolution of well-being of women who become widowed by comparing them with their matched non-widowed ‘statistical twins’ and examine the role of an exceptionally broad set of potential moderators of widowhood’s impact on well-being. We confirm a dramatic decrease in mental health and life satisfaction after the loss of a partner, followed by a slow recovery. An extensive set of controls recorded prior to widowhood, including detailed family ties and social networks, provides little help in explaining the deterioration in well-being. Unique data from time-diaries kept by older women from several European countries and the U.S. tell us why: the key factor behind widows’ reduced well-being is increased time spent alone.Presented by Dr. Michal Myck, Director, Centre for Economic Analysis, CenEA.

In preparation for the introduction of the new Aged Care Act and strengthened Quality Standards, this webinar will introduce the Commission’s new draft Regulatory Strategy that describes how we will deliver on our commitment to safeguard and protect older people, and how we hold providers and workers to account. It will advise providers and workers what we expect from them, and how we will engage with them. Importantly, it also tells older people and their families, as well as providers and workers what they can expect from us.SpeakersJanet Anderson, PSM, Aged Care Quality and Safety CommissionerLisa Peterson, PSM, Deputy Commissioner, Sector Capability and Regulatory Strategy, Aged Care Quality and Safety CommissionLouise Macleod, Complaints Commissioner, Aged Care Quality and Safety CommissionPeter Edwards, Executive Director, Compliance Management Group, Aged Care Quality and Safety CommissionEmma Jobson, Executive Director, Regulatory Policy and Intelligence, Aged Care Quality and Safety CommissionAnthony Speed, Executive Director, Quality Assessment and Monitoring, Aged Care Quality and Safety Commission

Delve into the innovative journey of developing a new medicine using the Inhaled Oxytocin project as a case study. This technology was devised and initially developed at Monash University and is now entering clinical development in collaboration with GSK and philanthropic funding partners. Our guest speaker, Associate Professor Pete Lambert, from the Department of Pharmacy and Pharmaceutical Sciences at Monash University, brings over 20 years of expertise in pharmaceutical product development.KEY TOPICS:- Development pathway for new medicines- Proof of concept- Phase 2 clinical development- Running not-for-profit programs- Partnering with pharmaceuticalsSPEAKER:Pete Lambert, Pharmacy and Pharmaceutical Sciences, Monash UniversityABOUT PETE LAMBERT:Peter is a pharmaceutical scientist and programme director specialising in global health R&D. He currently leads the inhaled oxytocin project seeking to develop a novel oxytocin product to better manage postpartum haemorrhage in low resource settings.He is also a co-coordinator of the Global Health Therapeutic Program Area at Monash Institute of Pharmaceutical Sciences.Originally trained as a pharmacist, Pete has 20+ years experience in product development in the pharmaceutical industry.

Join us for an insightful webinar where we will delve into the comprehensive vision of the ODIN project. This session will provide an in-depth look at the strategies developed to effectively integrate change management practices in hospital settings, alongside the barriers and challenges faced when introducing innovations into hospital processes.Key Details:Date: 10th JulyTime: Between 12pm and 1pm CET (60 minutes max)Presenter: MSc. Beatriz MerinoPresenter Profile: MSc. Beatriz Merino is a Biomedical Engineer specializing in Medical Images, with credentials from the Technical University of Madrid. She holds a Master’s in Biomedical Engineering with a focus on management and innovation in healthcare technologies, as well as a Master of Business Administration. Since 2017, she has been a researcher and project manager at the Life Supporting Technologies (LifeSTech) research group. Her research focuses on ICT in the Health domain and active and healthy aging, particularly chronic disease management and diabetes.Webinar Highlights:Detailed exploration of the ODIN project’s vision.Insights into the development and integration of change management practices in hospitals.Discussion of the barriers and challenges in implementing innovations in hospital processes.Don’t miss this opportunity to gain valuable knowledge and perspectives on managing change and innovation within the healthcare sector.

Hypersensitivity pneumonitis (HP), also known as extrinsic allergic alveolitis (EAA), is an immune-mediated interstitial lung disease triggered by inhaled antigens such as molds, bird feathers, and agricultural dusts. Often linked to working conditions, HP is a disease of many faces, from inflammatory self-limiting disease to relapsing or progressive inflammatory disease and chronic fibrotic disease. As there does not exist a single, universal diagnostic criterion, HP is diagnosed by a combination of findings established through clinical history, including imaging, histopathology, pulmonary function testing, bronchoscopy, and serology. With the rise of automated immunoassays capable of quantitatively measuring specific IgG to common HP antigens, an expanded diagnostic can be used to detect the potential triggering antigen.This webinar delves into the pathophysiology of HP, highlights the diagnostic criteria according to the current guidelines, and emphasizes the utility of specific IgG determination and the importance of cutoff values in HP.Key learning objectives:Describe the pathophysiology of hypersensitivity pneumonitisExplain the diagnostic criteria used to establish HPDiscuss the value of serology in HPAccreditation statementSelectScience is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.Presenters: Dora Wells (Editorial Team, SelectScience) and Dr. Johannes Grosch (Clinical Expert, Siemens Healthineers).